Indivior
PLC
Appointment of Independent
Non-Executive Director
Slough, UK, and Richmond,
VA, March 21, 2024 - The Board of
Indivior PLC (LSE/Nasdaq: INDV) today announces the appointment of
David E. Wheadon, M.D. as an Independent Non-Executive Director of
the Company with effect from June 1, 2024. Dr. Wheadon is a
health policy leader and physician with more than three decades of
global experience in the pharmaceutical industry.
Graham Hetherington, Chair,
commented:
'We are delighted to announce David's appointment as an
Independent Non-Executive Director. David has extensive experience
in the biopharmaceutical industry and expertise in global heath
policy and regulatory affairs, product quality and patient
safety. He will be a tremendous
asset as we continue to focus on our purpose of pioneering
life-transforming treatments for substance use disorders, serious
mental illness and accidental overdose.'
Dr. Wheadon previously served as
senior vice president of global regulatory affairs, patient safety,
and quality assurance at AstraZeneca Plc from December 2014 to July
2019. Prior to that, he was executive vice president, research and
advocacy at Juvenile Diabetes Research Foundation International
Inc., from May 2013 to December 2014, and senior vice president,
scientific and regulatory affairs at Pharmaceutical Research and
Manufacturers of America (PhRMA), from January 2009 to May 2013.
Dr. Wheadon served as vice president, global pharmaceutical
regulatory and medical science, and group vice president, global
pharmaceutical regulatory affairs at Abbott Laboratories from 2005
to 2009. Prior to Abbott Laboratories, Dr. Wheadon held senior
regulatory and clinical development leadership positions at
GlaxoSmithKline Plc and Eli Lilly and Company.
Dr. Wheadon received his M.D. from
Johns Hopkins University School of Medicine and an A.B. in Biology
from Harvard University. He completed his postdoctoral
training in Psychiatry at Tufts/New England Medical Center in
Boston, Massachusetts.
Dr. Wheadon is a Non-executive
Independent Director of Sotera Health Company (Nasdaq: SHC),
Vaxart, Inc (Nasdaq: VXRT), and ConnectiveRx. He also serves as a
member of the Board of Trustees of Mount Sinai Health System. Prior
to its recent acquisition by Bristol-Myers Squibb Company, Dr.
Wheadon served as a Non-executive Independent Director of Karuna
Therapeutics, Inc (NASDAQ: KRTX).
There is no further information to
disclose in relation to Dr. Wheadon's appointment in accordance
with LR 9.6.13.
About
Indivior
Indivior is a global pharmaceutical
company working to help change patients' lives by developing
medicines to treat addiction and serious mental illnesses. Our
vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of substance use disorder (SUD). Indivior is
dedicated to transforming SUD from a global human crisis to a
recognized and treated chronic disease. Building on its global
portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category
and potentially address other chronic conditions and co-occurring
disorders of SUD, including alcohol use disorder and cannabis use
disorder. Headquartered in the United States in Richmond, VA,
Indivior employs more than 1,100 individuals globally and its
portfolio of products is available in 37 countries worldwide.
Visit www.indivior.com to learn more. Connect with Indivior on
LinkedIn by visiting www.linkedin.com/company/indivior.
Media Contacts:
US Media:
Cassie France-Kelly
Vice President,
Communications
Indivior PLC
Tel: 804-724-0327
UK Media:
Teneo
Tel: +44 207-353-4200
Investors and
Analysts:
Jason Thompson
Vice President, Investor
Relations
Indivior PLC
Tel: 804-402-7123
Tim Owens
Director, Investor
Relations
Indivior PLC
Tel: 804-263-3978